FAKTOR-OPTIONSSCHEIN - GENMAB | Delayed Deutsche Boerse AG 12:06:10 2024-06-18 pm EDT | ||
| 0.26 EUR | 0.00% |
|
| Current month | +23.81% | ||
| 1 month | +36.84% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
GENMAB A/S
| Date | Price | Change |
|---|---|---|
| 24-06-18 | 0.26 | 0.00% |
| 24-06-17 | 0.26 | +4.00% |
| 24-06-14 | 0.25 | -3.85% |
| 24-06-13 | 0.26 | +4.00% |
| 24-06-12 | 0.25 | +8.70% |
Delayed Quote Deutsche Boerse AG
Last update June 18, 2024 at 12:06 pm EDT
More quotesStatic data
| Product type | Exotic Products |
|---|---|
| Buy / Sell | CALL |
| Underlying | GENMAB A/S |
| Issuer | 
Société Générale
|
| WKN | SB26YB |
| ISIN | DE000SB26YB8 |
| Date issued | 2020-07-21 |
| Strike | 2,324 kr |
| Maturity | Unlimited |
| Parity | 1 : 1 |
| Emission price | 1.36 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 1.67 € |
|---|---|
| Lowest since issue | 0.085 € |
| Spread | 0.01 € |
| Spread % | 3.70% |
Company Profile
Genmab A/S specializes in the research and development of human and therapeutic antibodies intended for treating cancers, infectious diseases, rheumatoid arthritis, etc. Net sales break down by type of income as follows:
- royalties (83.2%);
- income from research and development (12.4%);
- other (4.4%): primarily income from partnership agreement.
At the end of 2023, the group had a portfolio of more than 20 products in clinical development phase and 20 in preclinical development phase.
Denmark accounts for all net sales.
Sector
-
Consensus: Genmab A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
22
Last Close Price
1,800
DKK
Average target price
2,464
DKK
Spread / Average Target
+36.93%
- Stock Market
- Certificates
- Certificat
